CR20210389A - Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282) - Google Patents

Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)

Info

Publication number
CR20210389A
CR20210389A CR20210389A CR20210389A CR20210389A CR 20210389 A CR20210389 A CR 20210389A CR 20210389 A CR20210389 A CR 20210389A CR 20210389 A CR20210389 A CR 20210389A CR 20210389 A CR20210389 A CR 20210389A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
activity
Prior art date
Application number
CR20210389A
Other languages
English (en)
Inventor
Zandt Michael C Van
Eric B Sjogren
Jim Li
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of CR20210389A publication Critical patent/CR20210389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención se refiere a una nueva clase de compuestos que exhiben actividad inhibidora de la actividad hacia la arginasa, y composiciones farmacéuticas que comprenden los compuestos de la invención. También se proporcionan en el presente documento los métodos para tratar el cáncer con los inhibidores de arginasa de la invención.
CR20210389A 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282) CR20210389A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
CR20210389A true CR20210389A (es) 2021-09-16

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
CR20180282A CR20180282A (es) 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa
CR20210389A CR20210389A (es) 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)
CR20210390A CR20210390A (es) 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20180282A CR20180282A (es) 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20210390A CR20210390A (es) 2015-10-30 2016-10-28 Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)

Country Status (37)

Country Link
US (4) US10065974B2 (es)
EP (3) EP3693375B1 (es)
JP (3) JP6833844B2 (es)
KR (2) KR102434308B1 (es)
CN (4) CN108271371B (es)
AU (3) AU2016343656B2 (es)
BR (3) BR112018008746B1 (es)
CA (1) CA3003271A1 (es)
CL (4) CL2018001134A1 (es)
CO (1) CO2018004750A2 (es)
CR (3) CR20180282A (es)
CY (1) CY1123557T1 (es)
DK (2) DK3368541T3 (es)
EA (1) EA038276B1 (es)
EC (1) ECSP18040250A (es)
ES (3) ES2991555T3 (es)
HR (1) HRP20201046T1 (es)
HU (1) HUE054972T2 (es)
IL (3) IL258731B (es)
LT (1) LT3368541T (es)
MA (2) MA43131B1 (es)
MD (1) MD3368541T2 (es)
MX (1) MX2018005294A (es)
MY (1) MY201783A (es)
NZ (1) NZ742742A (es)
PE (1) PE20181776A1 (es)
PH (2) PH12022551082A1 (es)
PL (1) PL3368541T3 (es)
PT (1) PT3368541T (es)
RS (1) RS60695B1 (es)
SG (4) SG10201911406TA (es)
SI (1) SI3368541T1 (es)
SM (1) SMT202000469T1 (es)
TW (3) TWI734630B (es)
UA (1) UA125289C2 (es)
WO (1) WO2017075363A1 (es)
ZA (4) ZA201803556B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
KR20200008578A (ko) 2017-05-12 2020-01-28 칼리테라 바이오사이언시즈, 인코포레이티드 (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2019173188A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
EP3810615B1 (en) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
EP3880685B1 (en) 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
CN113614095B (zh) * 2019-02-06 2024-08-23 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的烷基硼酸类化合物
PH12021552036A1 (en) * 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
EP4004004A1 (en) * 2019-07-23 2022-06-01 AstraZeneca AB Arginase inhibitors and methods of use thereof
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
CN118286450A (zh) 2019-11-12 2024-07-05 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US20220041630A1 (en) 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
JP2025523364A (ja) * 2022-06-08 2025-07-23 デウン ファーマシューティカル カンパニー リミテッド アルギナーゼ阻害剤およびこれを含む薬学的組成物
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2024191996A1 (en) 2023-03-13 2024-09-19 Incyte Corporation Bicyclic ureas as kinase inhibitors
WO2026076207A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1
KR20260082235A (ko) * 2024-11-27 2026-06-04 주식회사 대웅제약 아르기나아제 저해제 및 이를 포함하는 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
WO2002004465A1 (en) 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1915143A4 (en) 2005-07-01 2009-11-11 Univ Johns Hopkins ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
WO2010085797A2 (en) * 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
SG11201503459SA (en) * 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
MA50636A (fr) 2021-04-14
EA038276B1 (ru) 2021-08-04
US10065974B2 (en) 2018-09-04
US10844080B2 (en) 2020-11-24
JP6833844B2 (ja) 2021-02-24
PL3368541T3 (pl) 2020-11-02
CN113150015A (zh) 2021-07-23
LT3368541T (lt) 2020-09-25
TW202110858A (zh) 2021-03-16
CN108271371B (zh) 2021-02-09
PT3368541T (pt) 2020-07-06
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
EA201891057A1 (ru) 2018-12-28
BR122020022280B1 (pt) 2022-05-03
JP2018533582A (ja) 2018-11-15
HUE054972T2 (hu) 2021-10-28
CL2019000820A1 (es) 2019-08-09
EP3368541A1 (en) 2018-09-05
MD3368541T2 (ro) 2020-09-30
KR20220118559A (ko) 2022-08-25
CN113150016A (zh) 2021-07-23
CL2019000819A1 (es) 2019-08-09
UA125289C2 (uk) 2022-02-16
ES2910928T3 (es) 2022-05-17
IL258731A (en) 2018-06-28
SG10201911402YA (en) 2020-02-27
ES2808988T3 (es) 2021-03-02
US20210061822A1 (en) 2021-03-04
HRP20201046T1 (hr) 2020-10-16
PH12018500899A1 (en) 2018-10-29
EP3368541A4 (en) 2019-07-17
US10851118B2 (en) 2020-12-01
MX2018005294A (es) 2018-09-21
CR20210390A (es) 2021-10-19
SG11201802961PA (en) 2018-05-30
IL258731B (en) 2021-04-29
CY1123557T1 (el) 2022-03-24
AU2016343656B2 (en) 2020-09-17
CO2018004750A2 (es) 2018-10-31
CL2018001134A1 (es) 2018-10-26
EP3693375B1 (en) 2022-02-16
CR20180282A (es) 2018-11-30
TWI775556B (zh) 2022-08-21
JP2021075543A (ja) 2021-05-20
MY201783A (en) 2024-03-18
CN108271371A (zh) 2018-07-10
PH12018500899B1 (en) 2023-02-08
TW202146028A (zh) 2021-12-16
DK4011887T3 (da) 2024-10-28
JP2022071010A (ja) 2022-05-13
KR102434308B1 (ko) 2022-08-19
TWI734630B (zh) 2021-07-21
ZA201907093B (en) 2021-03-31
EP4011887B1 (en) 2024-07-31
MA43131B1 (fr) 2020-07-29
AU2020286278B2 (en) 2022-03-17
BR112018008746A8 (pt) 2019-02-26
EP4011887A1 (en) 2022-06-15
AU2020286278A1 (en) 2021-01-14
PH12022551082A1 (en) 2023-03-13
ZA201907091B (en) 2021-05-26
US20170121352A1 (en) 2017-05-04
JP7032583B2 (ja) 2022-03-08
US20200223872A1 (en) 2020-07-16
RS60695B1 (sr) 2020-09-30
PE20181776A1 (es) 2018-10-31
WO2017075363A1 (en) 2017-05-04
TWI710565B (zh) 2020-11-21
ES2991555T3 (es) 2024-12-04
CL2019000821A1 (es) 2019-08-09
IL281503B (en) 2022-01-01
ZA201907092B (en) 2021-04-28
IL281503A (en) 2021-04-29
US20180346489A1 (en) 2018-12-06
IL288225A (en) 2022-01-01
BR122020022275B1 (pt) 2022-05-03
EP3693375A1 (en) 2020-08-12
ZA201803556B (en) 2021-02-24
AU2022203703A1 (en) 2022-06-16
CN113201002A (zh) 2021-08-03
SI3368541T1 (sl) 2020-10-30
AU2016343656A1 (en) 2018-06-07
ECSP18040250A (es) 2018-10-31
BR112018008746A2 (pt) 2018-10-30
TW201726692A (zh) 2017-08-01
SG10201911406TA (en) 2020-01-30
BR112018008746B1 (pt) 2021-11-16
CA3003271A1 (en) 2017-05-04
EP3368541B1 (en) 2020-05-27
SMT202000469T1 (it) 2020-11-10
HK1252560A1 (en) 2019-05-31
DK3368541T3 (da) 2020-06-29
KR20180084063A (ko) 2018-07-24

Similar Documents

Publication Publication Date Title
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
PH12022551082A1 (en) Compositions and methods for inhibiting arginase activity
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
PH12015502028A1 (en) Ido inhibitors
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
PH12016501462A1 (en) Neprilysin inhibitors
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12017501897A1 (en) 2-thiopyrimidinones
IN2014MU00495A (es)
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
EA201991517A1 (ru) Композиции и способы ингибирования активности аргиназы
WO2017023684A3 (en) Covalent irreversible inhibitors of usp7 as anti-cancer agents